64310-32-3

Basic information

• Product Name: Benzoic acid, 4-chloro-, 2-(aminothioxomethyl)hydrazide
• CAS NO: 64310-32-3
• Molecular Formula: C8H8ClN3OS
• Molecular Weight: 229.69
• Mol File: 64310-32-3.mol
• Article Data: 31

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-chloro-, 2-(aminothioxomethyl)hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-chloro-, 2-(aminothioxomethyl)hydrazide(64310-32-3)
• EPA Substance Registry System: Benzoic acid, 4-chloro-, 2-(aminothioxomethyl)hydrazide(64310-32-3)

Safety Data

• Hazardous Substances Data: 64310-32-3(Hazardous Substances Data)

Upstream product

• 1147550-11-5 ammonium thiocyanate 
• 536-40-3 4-chlorobenzoic acid hydrazide 
• 1126-46-1 Methyl 4-chlorobenzoate 
• 79-19-6 thiosemicarbazide 
• 2290-65-5 trimethylsilyl isothiocyanate 
• 74-11-3 para-chlorobenzoic acid 
• 333-20-0 potassium thioacyanate 
• 122-01-0 4-chloro-benzoyl chloride 

Downstream Products

• 129886-20-0 2-(p-chlorobenzoyl) hydrazono-4-thiazolidinone 
• 1363773-45-8 3-[4-(3-Chlorophenyl)piperazino]propyl [5-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl]sulfide 
• 1363773-46-9 5-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl 3-[4-(2-pyrimidinyl)piperazino]propyl sulfide 
• 76700-02-2 2-(p-Chloro-benzoyl)-hydrazino-4,5,6,7-tetrahydrobenzothiazole 
• 28004-62-8 2-amino-5-(4-chlorophenyl)-1,3,4-thiadiazole 
• 26028-65-9 5-(4-chloro-phenyl)-2,4-dihydro-[1,2,4]triazole-3-thione 
• 26028-65-9 5-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione 
• 47298-24-8 4-chloro-benzoic acid N'-(4-amino-5-phenyl-thiazol-2-yl)-hydrazide 
• 855737-94-9 1-(4-chloro-benzoyl)-S-methyl-iso thiosemicarbazide 
• 33621-61-3 2-amino-5-(4-chlorophenyl)-1,3,4-oxadiazole 
• 26028-65-9 5-(4-chloro-phenyl)-1,2-dihydro-[1,2,4]triazole-3-thione 
• 81516-43-0 7-methyl-2-(4-chlorophenyl)-5H-1,3,4-thiadiazolo<3,2-a>pyrimidin-5-one 
• 132719-42-7 6-Carboxy-2-(4-chlorphenyl)-5-methyl-thiazolo<3,2-b>-1,2,4-triazol 
• 132557-24-5 α-<(3-(4-Chlorphenyl)-1,2,4-triazol-5-yl)-thio>acetessigsaeureethylester 

Relevant articles and documents

Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction

Defective in cullin neddylation 1(DCN1) is a co-E3 ligase that is important for cullin neddylation. Dysregulation of DCN1 highly correlates with the development of various cancers. Herein, from the initial high-throughput screening, a novel hit compound 5a containing a phenyltriazole thiol core (IC50 value of 0.95 μM for DCN1-UBC12 interaction) was discovered. Further structure-based optimization leads to the development of SK-464 (IC50 value of 26 nM). We found that SK-464 not only directly bound to DCN1 in vitro, but also engaged cellular DCN1, suppressed the neddylation of cullin3, and hindered the migration and invasion of two DCN1-overexpressed squamous carcinoma cell lines (KYSE70 and H2170). These findings indicate that SK-464 may be a novel lead compound targeting DCN1-UBC12 interaction.

Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A2A receptor (A2AR) antagonist for benefit in Parkinson's disease

Various studies showed adenosine A2A receptors (A2ARs) antagonists have profound therapeutic efficacy in Parkinsons Disease (PD) by improving dopamine transmission, thus being active in reversing motor deficits and extrapyramidal symptoms related to the disease. Therefore, in the presents study, we have showed the development of novel 1,3,5-triazine-thiadiazole derivative as potent A2ARs antagonist. In the radioligand binding assay, these molecules showed excellent binding affinity with A2AR compared to A1R, with significant selectivity. Results suggest, compound 7e as most potent antagonist of A2AR among the tested series. In docking analysis with A2AR protein model, compound 7e found to be deeply buried into the cavity of receptor lined via making numerous interatomic contacts with His264, Tyr271, His278, Glu169, Ala63, Val84, Ile274, Met270, Phe169. Collectively, our study demonstrated 1,3,5-triazine-thiadiazole hybrid as a highly effective scaffold for the design of new A2A antagonists.

Identification of 1,2,4-triazoles as new thymidine phosphorylase inhibitors: Future anti-tumor drugs

Thymidine phosphorylase (TP) is over expressed in several solid tumors and its inhibition can offer unique target suitable for drug discovery in cancer. A series of 1,2,4-triazoles 3a–3l has been synthesized in good yields and subsequently inhibitory potential of synthesized triazoles 3a–3l against thymidine phosphorylase enzyme was evaluated. Out of these twelve analogs five analogues 3b, 3c, 3f, 3l and 3l exhibited a good inhibitory potential against thymidine phosphorylase. Inhibitory potential in term of IC50 values were found in the range of 61.98 ± 0.43 to 273.43 ± 0.96 μM and 7-Deazaxanthine was taken as a standard inhibitor with IC50 = 38.68 ± 4.42 μM. Encouraged by these results, more analogues 1,2,4-triazole-3-mercaptocarboxylic acids 4a–4g were synthesized and their inhibitory potential against thymidine phosphorylase was evaluated. In this series, six analogues 4b–4g exhibited a good inhibitory potential in the range of 43.86 ± 1.11–163.43 ± 2.03 μM. Angiogenic response of 1,2,4-triazole acid 4d was estimated using the chick chorionic allantoic membrane (CAM) assay. In the light of these findings, structure activity relationship and molecular docking studies of selected triazoles to determine the key binding interactions was discussed. Docking studies demonstrate that synthesized analogues interacted with active site residues of thymidine phosphorylase enzyme through π-π stacking, thiolate and hydrogen bonding interactions.